ESMO 2025

Confirmative OS data on CDK4/6 inibitors for pts with…

Rethinking dosing in TNBC

Toward a new standard - T-DXd in early breast cancer

Reassuring data on pregnancy for young EBC patients

T-DXd in high-risk patients in the postneoadjuvant…

POSITIVE trial - update

OS-benefit with abemaciclib

T-DXd neoadjuvant improves pCR

monarchE OS

Financial toxicity

New insights into PROTAC SERD vepdegestrant

The first neoadjuvant therapy decreases chemotherapy in…

CDK4/6 inhibitors – confirmed effect

Adjuvant data with CDK4/6 inhibitors in HR+ breast…

Optimizing G-CSF administration helps reducing side…

Optimal timepoint of G-CSF administration after…

Ki67 after preoperative chemotherapy - a new strong…

Exciting news for young patients who want to get…

Great update for young women

Durvalumab improves OS in TNBC

First time OS - confirming clinical practice

Individual consultation remains important

T-DXd right from the start – in a neoadjuvant situation…

monarchE OS

Studio POSITIVE - aggiornamento

Momento óptimo para la administración de G-CSF después…

Prima valutazione della OS: conferma della pratica…

Ki67 po przedoperacyjnej chemioterapii - nowy istotny…

Un primer paso hacia una gran historia

Practice changing data for firstline TNBC

Future perspectives for firstline therapy

ADCs in mBC - the story is not finished

TROP2 number 3

Another good option for patients with mTNBC

Changing the paradigm of treatment in 1L of TNBC

ADC, the first

Stronger together

Breakthroughs for high-risk patients

Survival data from SONIA

Gedatolisib in patients with PI3K wild type HR+ mBC

Transforming TNBC

TROP2 ADC, the second

Early positioning of third-generation ADCs in treatment

Reforming destiny

ADCs are coming for first line TNBC

Combination matters

Meeting the unmet need in advanced TNBC not eligible…

Should this drug be available outside of China?

Otra buena opción para pacientes con mTNBC

Gedatolisib in pazienti con mBC HR+ PI3K wild type

Più forti insieme

Gli ADC si fanno strada nella prima linea del TNBC

La combinazione conta

Nowa szansa dla chorych na zaawansowanego, potrójnie…

Gedatolisib chez les patients atteints d'un cancer du…

Positionnement plus précoce des ADCs de troisième…

Evolving immunotherapy approaches in locally advanced…

Immunotherapy and biomarkers in resectable NSCLC:…

New chances for locally advanced NSCLC

A bridge to surgery

FLAURA2: OS outcomes in poor-prognosis EGFRm NSCLC with…

Therapy sequencing after EGFR-TKI progression: insights…

ALEX: Long-term OS benefit with Alectinib in ALK+ NSCLC

New targeted therapies in HER2-mutated NSCLC

Is this the end for pembrolizumab?

Eradication of all disease - is this the true north?

Treat your BRAF-patients in 1L

Save and effective - Ivonescimab in HARMONi-6

Alectinib remains a potential SOC

HER2 altered - small population, many options

Anti-TROP-2 ADCS - new data in EGFRm NSCLC

The return of antiangiogenic strategy in squamous NSCLC

New treatment options for HER2-mutation positive NSCLC

ALK - longterm

Update for pts with BRAF mutation

New chances for locally advanced NSCLC

EGFR exon 20 - What does the future hold?

New options after EGFR-TKI failure

sac-TMT a new SOC

Sac-TMT now also available for NSCLC

Local therapy in addition to osimertinib 1st line in…

Is chemo-IO an option if you want a rapid response in…

The added value of radiotherapy in EGFR mutated NSCLC

Local ablative therapy in EGFR-mutated NSCLC

New prospect for squamous tumors

Ivonescimab in NSCLC - a new SOC?

Two frontline HER2-options - is this the future?

NorthStar - new navigation principle

New kid on the block for EGFRm

Sac-TMT - a potential new option for EGFRm NSCLC…

È la fine per Pembrolizumab?

De toegevoegde waarde van radiotherapie bij…

Due è meglio di uno

Sac - TMT - une nouvelle option potentielle pour le…

Le retour de la stratégie antiangiogénique dans le…

New kid on the block for EGFRm

Nuevas perspectivas para los tumores escamosos

Long-term outcomes with tepotinib in METex14 skipping…

Molecular factors and ctDNA dynamics linked to outcomes…

T-cell engager in 1st line SCLC

Will tarlatamab improve 1st line treatment for…

Dramatic improvement of PFS in 1L treatment

Tarlatamab combination in 1st line SCLC

DLL3 targeting drugs moving to frontline therapy

Zal tarlatamab de eerstelijnsbehandeling van…

Doblando la gravedad del SCLC

The hippo-pathway in Mesothelioma

Another part of the puzzle

A step in the right direction

Relevance of CPI neoadjuvant and adjuvant

Adjuvans in high risk RCC after surgery

Kidney cancer advances from ESMO

Further intensification of therapy with potential…

LenCabo - early activity, but we need more data

Therapy-relevant aspects for first-line treatment of…

More evidence in second-line treatment for metastatic…

The dawn of molecular imaging in renal cell carcinoma

NMIBC: Making the right choice for high risk patients!

MIBC: Is ctDNA monitoring ready for daily practice?

MIBC: Practice Changing data towards bladder…

Is ICI to BCG suitable for NMIBC?

Adding checkpoint inhibitor in high risk NMIBC shows…

When precision matters, the case of ctDNA in MIBC

Neoadjuvant combination of local and systemic therapy…

Negative, but important data to discuss

Dose modifications, new combinations, new substances in…

Therapy intensification in patients ineligible for…

Better QoL for patients with metastatic bladder cancer

Perioperative and adjuvant standards for MIBC

The ADC story continues

Setting the bar even higher in MIBC

Bladder cancer highlights from ESMO 2025

A highly selective FGFR3 inhibitor for first-line…

Too early for primetime

ADC Enfortumab vedotin + Pembrolizumab in MIBC

Neoadjuvant HER2-targeted therapy for kidney-sparing…

New options for neoadjuvant therapy in MIBC

A well-tolerated and effective new neoadjuvant concept…

De-escalation promotes a better QoL while maintaining…

A newcomer in advanced urothelial cancer

Un recién llegado en el cáncer urotelial avanzado

Données négatives, mais importantes à discuter

Elevando aún más el estándar en MIBC

Cuando la precisión importa: el caso de ctDNA en MIBC

A Game-Changer for Early Relapse?

Example for biomarker guided precision medicine in…

New docetaxel regimen in combination with darolutamide…

PSMAddition - Is it time for more?

Changed chemo-regimen leads to less toxicity in mHSPC

The role of lutetium in mHSPC – is its use clinically…

Impressive OS-data from EMBARK

Practice-changing data for mHSPC

OS-benefit in BCR

Triplet regimen with reduced chemotherapy – fewer side…

Final OS results for EMBARK

Exempel på biomarkörstyrd precisionsmedicin vid…

Imponerande OS-data från EMBARK

Social Listening